Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Peggy Benad-Mehner"'
Autor:
Maria Wilke, Andy Göbel, Martina Rauner, Peggy Benad-Mehner, Norbert Schütze, Susanne Füssel, Peyman Hadji, Lorenz C. Hofbauer, Tilman D. Rachner
Publikováno v:
Journal of Bone Oncology, Vol 3, Iss 1, Pp 10-17 (2014)
Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases. Direct antitumor effects
Externí odkaz:
https://doaj.org/article/b756a4b66b41474d8977d9443cecb1e8
Autor:
Peggy Benad-Mehner, Stefanie Thiele, Tilman D. Rachner, Andy Göbel, Martina Rauner, Lorenz C. Hofbauer
Publikováno v:
Journal of Bone Oncology, Vol 3, Iss 1, Pp 18-24 (2014)
Background: Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression i
Externí odkaz:
https://doaj.org/article/51b6e63854de48e29bbc6652c27ea425
Publikováno v:
Cancer Letters. 346:172-177
Bone metastases are a common problem of many malignancies, including myeloma, breast and prostate cancer. The Wnt inhibitor Dickkopf-1 has been shown to be involved in the process of bone lesions by impairing osteoblast activity. This review will foc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5609f14762fc5716674af0fa946276c
https://doi.org/10.1016/j.canlet.2014.01.010
https://doi.org/10.1016/j.canlet.2014.01.010
Autor:
Tilman D. Rachner, Peggy Benad-Mehner, Martina Rauner, Andy Göbel, Lorenz C. Hofbauer, Stefanie Thiele
Publikováno v:
Journal of Bone Oncology, Vol 3, Iss 1, Pp 18-24 (2014)
Journal of Bone Oncology
Journal of Bone Oncology
Background: Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::077fd491917abdf6d5b8b20d2ec4bc21
http://www.sciencedirect.com/science/article/pii/S2212137413000651
http://www.sciencedirect.com/science/article/pii/S2212137413000651
Autor:
Maria Wilke, Tilman D. Rachner, Lorenz C. Hofbauer, Norbert Schütze, Peggy Benad-Mehner, Susanne Füssel, Martina Rauner, Peyman Hadji, Andy Göbel
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 3, Iss 1, Pp 10-17 (2014)
Journal of Bone Oncology, Vol 3, Iss 1, Pp 10-17 (2014)
Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases. Direct antitumor effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2ffc9dd4f1126f010feed87c3bc923a
https://pubmed.ncbi.nlm.nih.gov/26909293
https://pubmed.ncbi.nlm.nih.gov/26909293
Autor:
Peggy Benad-Mehner, Andy Göbel, Maria Junker, Lorenz C. Hofbauer, Peyman Hadji, Tilman D. Rachner, Josefa Hötzel
Publikováno v:
Journal of Bone Oncology
Aminobisphosphonates are used for the treatment of benign and malignant bone disorders. As inhibitors of the mevalonate pathway they exert direct anti-tumor effects in vitro and in preclinical models of bone metastases. Bisphosphonates are thought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ecfca3a18104a6496c263a3a1c86a6
https://pubmed.ncbi.nlm.nih.gov/26909280
https://pubmed.ncbi.nlm.nih.gov/26909280
Publikováno v:
Frontiers in Microbiology; 11/1/2021, Vol. 12, p1-10, 10p